Last Participant Randomized in Phase III DEEp SEA Trial for Bexicaserin in Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby
@newsen.bsky.social
@newsen.bsky.socialLast Participant Randomized in Phase III DEEp SEA Trial for Bexicaserin in Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby
@newsen.bsky.socialLundbeck Reaches Significant Milestone in Bexicaserin Trial for Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby
@newsen.bsky.socialLundbeck Unveils Key Insights on Bexicaserin's Unique Mechanism at the European Epilepsy Congress #Denmark #Lundbeck #bexicaserin #Valby #DEEp_Program
@newsen.bsky.socialLundbeck to Showcase Bexicaserin's Innovative Dual Action Mechanism at European Epilepsy Congress #Denmark #Lundbeck #bexicaserin #Valby #Epilepsy_Congress